23 Jul, 2026
According to Straits Research, the global protein engineering market size was valued at $2.52 billion in 2025 and is projected to grow from $2.71 billion in 2026 to $4.81 billion by 2034 at a CAGR of 7.42% during the forecast period 2026–2034.
Protein engineering entails designing and producing unnatural polypeptides, frequently by transforming the amino acid sequences found in nature to create useful or valuable proteins. It utilizes recombinant DNA technology to alter amino acid sequences for novel and enhanced functions. It is a new discipline in which much research is devoted to understanding protein folding and identifying protein design principles. Numerous enzymes' industrial catalytic efficacy has been enhanced through protein engineering.
Therapeutic proteins are extraordinarily effective at alleviating diseases and are in high demand. According to a report published by La Merie Publishing (Germany) in March 2021, sales of proteins and biosimilar antibodies reached USD 240 billion in 2020, an increase of 7.5% from 2019.
Moreover, as per the National Institutes of Health of the United States, in January 2020, monoclonal antibodies (mAbs) accounted for more than 45 percent of all therapeutic proteins sold in the European Union and have applications in the treatment of several chronic diseases, including cancer, diabetes, multiple sclerosis, and asthma. Thus, the rising prevalence of chronic diseases will drive market growth over the forecast period.
Emerging markets such as Asia-Pacific are anticipated to drive the global market. This results from factors such as an improving healthcare infrastructure, a large number of Contract Research Organizations (CROs), and government programs and funding for protein-based drug development. Substantial investments are being made in the region's research for COVID-19 treatments, which will contribute to expanding the market.
Moreover, as per the American Cancer Society, Inc. (US), 8.2 million new cancer cases and 5.2 million cancer-related deaths were estimated in Southern, Eastern, and Southeast Asia in 2018. Similarly, according to the Journal of Diabetology (August 2018), an estimated 80 million persons in Southeast Asia had diabetes in 2017, expected to increase to 151 million by 2045. The region's increased prevalence of chronic diseases is anticipated to generate market expansion opportunities over the forecast period.
Americas is the most significant global protein engineering market shareholder and is anticipated to exhibit a CAGR of 4.56% during the forecast period. The dominance of the Americas can be ascribed to an increase in biotechnology and pharmaceutical companies, in R&D capabilities, in the concentration of the main market players, and in the availability of the most advanced techniques and instruments for drug use discovery research. The Americas consist of the continents of North America and South America. Further, the North American market has been divided between the United States and Canada. In the United States, the market for protein engineering is driven by the availability of technologically sophisticated devices and instruments and the concentration of the industry's key players.
In addition, increased research and development funding in Canada fuels the expansion of the protein engineering market. The expanding pharmaceutical industry in the region is a major factor propelling the South American protein engineering market. The high prevalence of lifestyle diseases and increased government support for R&D also contribute to expanding the market. According to Statista, Brazil had the largest pharmaceutical market in South America in 2019, reflecting the industry's accelerated expansion.
sales@straitsresearch.com